Information Provided By: 
Fly News Breaks for September 12, 2018
ZGNX
Sep 12, 2018 | 08:57 EDT
Northland analyst Carl Byrnes initiated Zogenix with an Outperform and $70 price target saying ZX008 is positioned to emerge as the 1st-line adjunctive therapy for patients with Dravet syndrome, achieving high market penetration. Byrnes is forecasting peak us US sales from the Dravet syndrome indication of $225M, with peak global sales for the indication at $500MM. Importantly, ZX008 has peak global sales potential greater than $2B, inclusive of other epileptic indications, the analyst wrote in a note to investors.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
